BioVie Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
BIVI
- Investments
-
2
- Share Price
-
$1.19
- (As of Thursday Closing)
BioVie General Information
Description
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Contact Information
Website
www.bioviepharma.comCorporate Office
- 680 West Nye Lane
- Suite 2014
- Carson City, NV 89703
- United States
Corporate Office
- 680 West Nye Lane
- Suite 2014
- Carson City, NV 89703
- United States
BioVie Stock Performance
As of 12-Nov-2026, BioVie’s stock price is $1.19. Its current market cap is $12.8M with 10.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.19 | $1.26 | $0.82 - $3.79 | $12.8M | 10.7M | 2.53M | -$2.85 |
BioVie Financials Summary
As of 30-Sep-2026, BioVie has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 4,496 | 1,828 | (5,608) | 2,563 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (22,896) | (22,473) | (17,833) | (30,134) |
| Net Income | (22,590) | (22,073) | (17,542) | (32,121) |
| Total Assets | 11,038 | 14,250 | 21,562 | 25,208 |
| Total Debt | 254 | 275 | 350 | 6,111 |
BioVie Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioVie Comparisons
Industry
Financing
Details
BioVie Competitors (80)
One of BioVie’s 80 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Madrigal Pharmaceuticals | Formerly VC-backed | West Conshohocken, PA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Allena Pharmaceuticals | Formerly VC-backed | Newton, MA |
BioVie Patents
BioVie Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026102125-A1 | Neurosteroid compounds and uses of the same | Pending | 07-Nov-2024 | ||
| WO-2025188648-A1 | Methods for the treatment of biological aging | Pending | 04-Mar-2024 | ||
| WO-2025188648-A8 | Methods for the treatment of biological aging | Pending | 04-Mar-2024 | ||
| WO-2025155561-A1 | Methods of treating long covid | Pending | 16-Jan-2024 | ||
| US-20250340941-A1 | Assay and methods for drug discovery | Pending | 13-Jan-2023 | C12Q1/6883 |
BioVie Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioVie Investments & Acquisitions (2)
BioVie’s most recent deal was a Corporate Asset Purchase with NeurMedix (Biopharmaceutical Assets in San Diego, California) for . The deal was made on 10-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NeurMedix (Biopharmaceutical Assets in San Diego, California) | 10-Jun-2021 | Corporate Asset Purchase | Buildings and Property | ||
| LAT Pharma | 11-Apr-2016 | Merger/Acquisition | Drug Discovery |
BioVie ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.81 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
BioVie FAQs
-
When was BioVie founded?
BioVie was founded in 2013.
-
Where is BioVie headquartered?
BioVie is headquartered in Carson City, NV.
-
What is the size of BioVie?
BioVie has 13 total employees.
-
What industry is BioVie in?
BioVie’s primary industry is Pharmaceuticals.
-
Is BioVie a private or public company?
BioVie is a Public company.
-
What is BioVie’s stock symbol?
The ticker symbol for BioVie is BIVI.
-
What is the current stock price of BioVie?
As of 12-Nov-2026 the stock price of BioVie is $1.19.
-
What is the current market cap of BioVie?
The current market capitalization of BioVie is $12.8M.
-
Who are BioVie’s competitors?
Pliant Therapeutics, Ardelyx, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Allena Pharmaceuticals are some of the 80 competitors of BioVie.
-
What is BioVie’s annual earnings per share (EPS)?
BioVie’s EPS for 12 months was -$2.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
